Following the release of top-line data from Kite Pharma Inc (NASDAQ: KITE)'s ZUMA-1 trial of its lead CAR T drug KTE-C19 at the European Society of Clinical Oncology, Goldman Sachs said the focus now shifts toward commercial outlook. The drug is being tested for relapsed/refractory lymphoma.
Analyst Salveen Richter said she expects the company's chief compliance officer Shawn Tomasello to shed light on payor discussions, Kite's market research and the potential launch trajectory at the R&D day to be held in New York on October 18. The analyst also expects to have more clarity on capacity at launch.
Additionally, the analyst expects the company to disclose its first target from the Amgen, Inc. (NASDAQ: AMGN) CAR T collaboration and provide an overview of the second wave of KTE-C19 indications.
Analyzing the trial results, Goldman Sachs noted that ZUMA-1 phase 2 interim pivotal data showed a three-month CR rate of 33 percent. The firm expects to see durability of at least six months in the full presentation scheduled for December 3–6. If the Phase 1 precedents translates to Phase 2, the firm believes a FDA approval of KTE-C19 is likely.
Goldman Sachs has a Buy rating on the shares of the company and a $70 price target.
At last check, shares of Kite Pharma were up 0.13 percent at $55.73.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email email@example.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for AMGN
|Aug 2016||Initiates Coverage on||Hold|
View More Analyst Ratings for AMGN
View the Latest Analyst Ratings
See more from Benzinga
- Chardan Rates Regeneron A Sell, Advises Caution
- Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.